Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy 2019 | Immune-mediated mechanisms of progression in MGUS and smouldering myeloma

Irene Ghobrial • 16 May 2019
COMy 2019
Multiple Myeloma Rare Diseases Smoldering Myeloma

Irene Ghobrial, MD, from the Dana-Farber Cancer Institute, Boston, MA, discusses the role of the immune microenvironment in the progression of smoldering myeloma and monoclonal gammopathy of unknown significance to overt disease. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

More from Irene Ghobrial

The latest updates in the pre-malignant space: the PROMISE study and the potential of immunotherapy 0:57
The latest updates in the pre-malignant space: the PROMISE study and the potential of immunotherapy
Irene Ghobrial • 6 Dec 2025
Results of the PROMISE study of ~30,000 individuals screened for monoclonal gammopathies 1:59
Results of the PROMISE study of ~30,000 individuals screened for monoclonal gammopathies
Irene Ghobrial • 6 Dec 2025
MGIP as a stable premalignant entity preceding hematologic malignancy 2:23
MGIP as a stable premalignant entity preceding hematologic malignancy
Irene Ghobrial • 6 Dec 2025
Risk stratification in smoldering myeloma: current standards and emerging advances 1:05
Risk stratification in smoldering myeloma: current standards and emerging advances
Irene Ghobrial • 17 Sep 2025

Related Videos

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals